Wakefit Innovations and Corona Remedies are set to hit the primary market with their initial public offerings (IPOs) for public subscription on Monday.

Grey market indicators showed firm interest ahead of the launches. Platforms tracking unofficial market activity pegged the grey market premium (GMP) for both issues as high as 31 percent.

Investorgain quoted a GMP of Rs 330 for Corona Remedies, implying a potential listing gain of about 31 percent, while Wakefit’s GMP stood at more than 18 percent.

Corona Remedies, a pharmaceutical company backed by private equity firm ChrysCapital, has fixed a price band of Rs 1,008–1,062 per share for its IPO, valuing the firm at around Rs 6,500 crore.

The Rs 655.37-crore issue is an offer for sale by promoters and existing shareholders. The offer wi

See Full Page